SOURCE: CNS Response, Inc.

CNS Response, Inc.

May 03, 2010 12:33 ET

Voting Results of Annual Meeting Announced by CNS Response

ALISO VIEJO, CA--(Marketwire - May 3, 2010) -  CNS Response, Inc. (OTCBB: CNSO), a life-sciences data company, today announced the voting results of its 2009 Annual Meeting of Shareholders held April 27, 2010, in Aliso Viejo, California. The Company's shareholders of record, as of March 24, 2009, approved two proposals, as listed in the CNS Response Definitive Proxy Statement filed with the Securities and Exchange Commission on April 1, 2010. Approximately 58.8 percent of all stockholders participated. 

CNS Response shareholders approved the appointments of five nominees to the Company's board of directors. These nominees included John Pappajohn, Henry Harbin, David Jones, Jerry Vaccaro and George Carpenter. Their appointments were approved by an average of 97 percent of the shares voted.

The second proposal, an approval for amending the company's 2006 Stock Incentive Plan to increase the number of shares of common stock that may be issued pursuant to awards granted under the plan from 10 million to 20 million shares, and to increase the number of shares that may be subject to awards granted under the plan to any one participant during any fiscal year from 3 million to 4 million, was approved by 89 percent of the shares voted.

CNS Response CEO George Carpenter presented a company update after the formal meeting. Shareholders who could not attend are invited to view the meeting video on our website,

About CNS Response
Today, most physicians are able to base treatment on objective test data, such as EKGs, MRIs, blood tests, etc. Broadly speaking, such advances have not yet come to those physicians practicing psychiatry.

CNS Response has developed a patented data-analysis capability that, with the help of a simple, non-invasive EEG, will analyze a patient's brain waves and compare the results to an extensive patient outcomes database. The process produces a rEEG® report providing a psychiatrist with guidance to personalize medication regimens for a patient, based on the patient's own brain physiology. To read more about the benefits this patented technology provides physicians, patients and insurers, please visit the CNS Response website,

Contact Information

  • Investor Relations:
    Marty Tullio
    Managing Partner
    McCloud Communications, LLC
    Email Contact